Facilitating the Behavioral Treatment of Cannabis Use Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02946489|
Recruitment Status : Completed
First Posted : October 27, 2016
Results First Posted : February 11, 2020
Last Update Posted : February 11, 2020
|Condition or disease||Intervention/treatment||Phase|
|Cannabis Dependence||Drug: CI-581a||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Single Group Assignment|
|Masking Description:||Open label single-blind trial, with participants given the impression they may get any of several medications.|
|Official Title:||Facilitating the Behavioral Treatment of Cannabis Use Disorder|
|Actual Study Start Date :||October 2016|
|Actual Primary Completion Date :||August 2018|
|Actual Study Completion Date :||August 2018|
Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
CI-581a will be administered in wk2 and potentially in wk 3 or 4.
- Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use [ Time Frame: At Week 6 (End of study) ]Percentage of participants with cannabis abstinence or significant reduction in cannabis use by end of study. Significant reduction in cannabis use was defined as: At least 50% reduction in cannabis use between pre-infusion and end of 6 week study.
- Confidence in Abstaining From Cannabis [ Time Frame: Change between pre-infusion and end of 6 week study ]Change in confidence in abstaining from cannabis as measured by the DCQ (Drug-Taking Confidence Questionnaire). DCQ is a scale from 0 to 100, with higher values indicating greater confidence in one's ability to abstain from cannabis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02946489
|United States, New York|
|New York, New York, United States, 10032|
|Principal Investigator:||Elias Dakwar, MD||Columbia University Irving Medical Center|